Athersys Inc ATHX:NASDAQ

Last Price$0.71NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.01(1.44%)
Bid (Size)$0.72 (20)
Ask (Size)$0.73 (7)
Day Low / High$0.68 - 0.73

View Biotechnology IndustryPeer Comparison as of 05/18/2022


Athersys Inc ( NASDAQ )

Price: $0.71
Change: -0.01 (1.44%)
Volume: 245.00
4:00PM ET 5/18/2022

Scholar Rock Holding Corp ( NASDAQ )

Price: $5.28
Change: -0.71 (11.85%)
Volume: 663.5 K
4:00PM ET 5/18/2022

Cogent Biosciences Inc ( NASDAQ )

Price: $4.17
Change: +0.03 (0.72%)
Volume: 186.4 K
4:00PM ET 5/18/2022

XBiotech Inc ( NASDAQ )

Price: $5.62
Change: -0.34 (5.70%)
Volume: 133.0 K
4:00PM ET 5/18/2022

Personalis Inc ( NASDAQ )

Price: $4.33
Change: -0.48 (9.98%)
Volume: 447.2 K
4:00PM ET 5/18/2022

Read more news Recent News

-- Earnings Flash (ATHX) ATHERSYS Posts Q1 Revenue $2.9M, vs. Street Est of $1.38M
8:03AM ET 5/06/2022 MT Newswires


Athersys Files $250 Million Mixed Shelf
4:18AM ET 5/06/2022 MT Newswires

Athersys (ATHX) on Thursday filed a shelf registration statement for the potential sale of up to $250 million of its securities from time to time. The...

Top Premarket Decliners
8:00AM ET 4/12/2022 MT Newswires

Myovant (MYOV) shares slumped 21% after the US Food and Drug Administration flagged certain deficiencies in the company's supplemental new drug application...

Top Premarket Decliners
8:10AM ET 4/04/2022 MT Newswires

Curis (CRIS) shares slumped 32% after the company said the US Food and Drug Administration placed the company's leukemia drug on partial clinical hold....

View all Commentary and Analysis

Athersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking Alpha

Athersys - Hero Or Zero Opportunity
10:56AM ET 4/18/2022 Seeking Alpha

Athersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript
8:47PM ET 3/15/2022 Seeking Alpha

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
2:34PM ET 1/20/2022 Seeking Alpha

Company Profile

Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
Address3201 Carnegie Avenue
Cleveland, Ohio 44115-2634
Number of Employees75
Recent SEC Filing05/12/2022424B5
Chief Executive Officer & DirectorDaniel A. Camardo
President & Chief Operating OfficerWilliam B. J. Lehmann
Chief Financial & Accounting OfficerIvor MacLeod
Director, Chief Scientific Officer & Executive VPJohn J. Harrington

Company Highlights

Price Open$0.72
Previous Close$0.71
52 Week Range$0.46 - 1.81
Market Capitalization$179.4 M
Shares Outstanding252.0 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.35
Beta vs. S&P 500N/A
Revenue$24.3 M
Net Profit Margin-981.52%
Return on Equity-429.24%

Analyst Ratings as of 11/18/2021

Consensus RecommendationConsensus Icon
Powered by Factset